

Roland Klingenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6093080/publications.pdf>

Version: 2024-02-01

45
papers

1,947
citations

361045

20
h-index

253896

43
g-index

45
all docs

45
docs citations

45
times ranked

4288
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. <i>European Heart Journal</i> , 2016, 37, 1967-1976.	1.0	433
2	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. <i>European Heart Journal</i> , 2017, 38, ehw582.	1.0	317
3	Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. <i>European Heart Journal</i> , 2009, 30, 2838-2844.	1.0	149
4	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2015, 36, 2438-2445.	1.0	129
5	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2016, 37, 546-553.	1.0	120
6	Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2017, 38, ehw563.	1.0	77
7	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 129-138.	0.4	70
8	Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes. <i>European Heart Journal</i> , 2015, 36, 1041-1048.	1.0	48
9	Decreased phosphatidylcholine plasmalogens – A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. <i>Atherosclerosis</i> , 2016, 246, 130-140.	0.4	47
10	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. <i>European Heart Journal</i> , 2017, 38, 3493-3502.	1.0	46
11	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. <i>Cardiovascular Research</i> , 2018, 114, 1178-1188.	1.8	44
12	Increased Proangiogenic Activity of Mobilized CD34 ⁺ Progenitor Cells of Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 341-349.	1.1	40
13	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. <i>Heart</i> , 2015, 101, 854-863.	1.2	38
14	Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1872-1879.	1.1	36
15	Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2018, 270, 7-13.	0.8	33
16	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 59-65.	0.8	30
17	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	29
18	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. <i>PLoS ONE</i> , 2014, 9, e93147.	1.1	28

#	ARTICLE	IF	CITATIONS
19	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13117.	1.7	24
20	Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. <i>Atherosclerosis</i> , 2016, 247, 154-160.	0.4	22
21	Inflammation during acute coronary syndromes – Risk of cardiovascular events and bleeding. <i>International Journal of Cardiology</i> , 2019, 287, 13-18.	0.8	22
22	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. <i>PLoS ONE</i> , 2018, 13, e0195174.	1.1	21
23	Low statin use in adults hospitalized with acute coronary syndrome. <i>Preventive Medicine</i> , 2015, 77, 131-136.	1.6	18
24	Prognostic value of pulse pressure after an acute coronary syndrome. <i>Atherosclerosis</i> , 2018, 277, 219-226.	0.4	15
25	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11
26	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1002.	1.0	11
27	Extracellular vesicle species differentially affect endothelial cell functions and differentially respond to exercise training in patients with chronic coronary syndromes. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1467-1474.	0.8	11
28	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 855-865.	0.4	9
29	Controlled-Level Everolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. <i>American Heart Journal</i> , 2022, 247, 33-41.	1.2	8
30	Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 522-531.	0.4	7
31	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 589-598.	0.4	7
32	Prognostic value of total testosterone levels in patients with acute coronary syndromes. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 235-242.	0.8	7
33	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021, 320, 31-37.	0.4	7
34	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. <i>PLoS ONE</i> , 2019, 14, e0211464.	1.1	6
35	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. <i>International Journal of Cardiology</i> , 2020, 303, 8-13.	0.8	5
36	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 445-452.	0.4	5

#	ARTICLE	IF	CITATIONS
37	Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute) Tj ETQq1 1 0.784314 rgBT Heart Association, 2021, 10, e020488.	1.6	4
38	Risk stratification of elderly patients with acute pulmonary embolism. European Journal of Clinical Investigation, 2019, 49, e13154.	1.7	3
39	Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography. Catheterization and Cardiovascular Interventions, 2019, 93, 16-24.	0.7	3
40	Rapid Inflammasome Activation Is Attenuated in Post-Myocardial Infarction Monocytes. Frontiers in Immunology, 2022, 13, 857455.	2.2	3
41	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. Nicotine and Tobacco Research, 2023, 25, 58-65.	1.4	2
42	Acute rupture of a thin cap fibroatheroma: value of multimodality imaging. European Heart Journal, 2015, 36, 1001-1001.	1.0	1
43	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International Journal of Cardiology, 2020, 299, 289-295.	0.8	1
44	High-sensitivity Troponins – Difficult Friends in Acute Coronary Syndromes. US Cardiology Review, 2012, 9, 121-125.	0.5	0
45	Coronary stent thrombosis in acute coronary syndromes. Cardiovascular Medicine(Switzerland), 0, , .	0.1	0